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OBJECTIVES: Our study aimed to investigate the impact of fatigue on the severity of stroke and to explore the
underlying mechanisms.
METHODS: Fatigued male rats underwent middle cerebral artery occlusion and the infarcted brain area was
determined. Then, coagulation parameters were assessed in the fatigued group and a control group. In
addition, the level of fibrinogen was determined in rats deprived of sleep for various numbers of days. To study
whether interleukin-6 was involved in fibrinogen synthesis during fatigue, we also measured levels of
interleukin-6 in rats deprived of sleep for various numbers of days. Furthermore, brain injury by middle cerebral
artery occlusion was measured in wild-type mice, interleukin-6-/- mice and wild-type mice treated with
bezafibrate.
RESULTS: More severe cerebral infarction was observed in the fatigued rats, resulting in an infarct ratio of
23.4%. The infarct ratio was significantly increased in the fatigued rats compared with that in the control group
(8%, p,0.05). The level of fibrinogen was increased significantly in the fatigued rats compared with that in the
control group. In addition, a marked reduction in fibrinogen level was observed in the fatigued interleukin-6-/-
mice compared to their wild-type counterparts, whereas no difference was observed between fatigued wild-
type mice and interleukin-6-/- rats treated with recombinant human interleukin-6. The reduction in brain injury
due to middle cerebral artery occlusion during fatigue was observed in interleukin-6-/- mice and wild-type mice
treated with bezafibrate.
CONCLUSION: Fatigue could increase stroke severity and was associated with the interleukin-6-induced
expression of fibrinogen.
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& INTRODUCTION
Fatigue has been found to be prevalent in the general
population, and it is an important symptom of mental and
stress-related health complaints (1-3). The high prevalence of
this condition in the general population has led to a growing
interest in the influence of clinical and sociodemographic
factors on the level of fatigue experienced by individuals (4,5).
In previous studies, fatigue was shown to be strongly
associated with bad mental health states, impaired functioning
and a variety of long-term illnesses; it is also a central
symptom in many diseases, such as ischemic heart disease,
cancer and depression (6-10). It has been reported that fatigue
is the most common prodromal symptom before acute
myocardial infarction, and preinfarction fatigue could con-
tribute to early left ventricular dysfunction (11,12). In addition,
fatigue is also a common symptom following a stroke (13,14).
Numerous studies have confirmed that severe fatigue after
stroke usually predicts a bad prognosis and an increased risk
of recurrent stroke (15,16). However, few studies have
examined the influence of fatigue on the severity of acute
ischemic events, such as acute ischemic stroke. Therefore, our
study aimed to investigate the impact of fatigue on the severity
of stroke and to explore the underlying mechanisms.
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& MATERIALS AND METHODS
Animals
Rats and mice were housed in a controlled environment
and provided access to standard rodent chow and water.
The animal care practices were in compliance with Chinese
regulations on the protection of animals used for experi-
mental and other scientific purposes.
Experimental groups
To study the effects of fatigue on the cerebral infarction
area, two groups of Sprague-Dawley rats were assigned
randomly to control and fatigued groups. To study whether
IL-6 was involved in the synthesis of fibrinogen during
fatigue, rats and mice were randomly assigned to four
groups and six groups, respectively. Each group of rats was
deprived of sleep for a different length of time: no sleep
deprivation (control), sleep deprivation for one day (F1),
sleep deprivation for three days (F3) and sleep deprivation
for five days (F5). The six groups of mice included wild-type
mice, fatigued wild-type mice, IL-6-/- mice, fatigued IL-6-/-
mice, IL-6-/- mice treated with IL-6 and fatigued IL-6-/- mice
treated with IL-6. To study whether the decreased expres-
sion of fibrinogen could affect the infarction area, three
groups of mice were tested: a fatigued group, a fatigued IL-
6-/- group and a fatigued group treated with bezafibrate.
All of the studies included six rats or mice per group.
Fatigue model
Male Sprague-Dawley rats were deprived of rest for five
consecutive days in a cage filled with water to a height of
1.5 cm, as described previously (18). The cage was
485x350x200 mm, and there was a heater placed underneath
it to keep the water warm. Under these conditions, the rats
were unable to assume a resting position while avoiding the
water, and they progressively grew fatigued.
MCAO model and evaluation of infarcted area
After fatigue treatment (five days of sleep deprivation),
male Sprague-Dawley rats underwent the MCAO proce-
dure described by Longa et al. (17). Briefly, the rats were
anesthetized with ketamine and xylazine, and the left
common carotid artery was exposed. Then, the external
carotid artery and its branches were isolated and coagu-
lated. A 3-0 Nylon suture with a blunted tip was inserted
into the internal carotid artery through the external carotid
artery stump and then advanced to the anterior cerebral
artery to occlude the middle cerebral artery (MCA). The
skin was then sutured, and the rats were allowed to awaken.
Twenty-four hours after the operations, the rats were
sacrificed, and coronal sections of the brain (2 mm thick)
were cut and immersed in a 2% solution of 2,3,7-
triphenyltetrazolium chloride. The stained slices were then
fixed by immersion in phosphate-buffered 4% paraformal-
dehyde. The infarcted area and hemispheric area of each
section were traced and measured using an image-analysis
system (a Macintosh computer running the public domain
National Institutes of Health Image program, written by
Wayne Rasband and available on the Internet). The
percentage of infarction (infarct ratio) was calculated by
dividing the infarcted area by the total area of the ipsilateral
hemisphere.
Measurement of coagulation parameters
Blood samples were obtained from the rats via a nonhepar-
inized venous catheter in the femoral vein. APTT, PT and TT
(Taiyang Biotechnology Company, Shanghai, China) were
measured automatically from clotting tests using commercial
reagents, and the test results were reported in seconds. The
default settings for the minimal/maximal measuring times for
APTT and TT were 3/120 sec and 13/240 sec, respectively.
Fibrinogen was detected using Claus’s method with a human
plasma calibration standard provided by the manufacturer.
Measurements of IL-6 in serum and CSF
The levels of IL-6 in the serum/CSF were measured using
commercially available ELISA kits (IL-6, Fuji Lebio, Tokyo,
Japan). The kit had a sensitivity limit of 4 pg/ml, and no
detectable IL-6 was found in sera from control mice or IL-6
knockout mice.
Animal treatment
Male IL-6-/- mice, weighing 18-22 g, were kept on a 12-h
day/night rhythm with free access to water and standard
rodent chow. The animals were injected daily with 0.02 mg
of rhIL-6/g body weight in a 0.9% NaCl solution containing
0.1% mouse serum albumin (MSA) or with only the 0.9%
NaCl/0.1% MSA solution at the start of sleep deprivation,
and the treatment lasted five days.
Bezafibrate was suspended in 1% methylcellulose solu-
tion and administered at a dose of 10 mg/kg/day orally at
the start of sleep deprivation and the treatment lasted five
days. The same amount of methylcellulose vehicle solution
was also administered orally as a control.
CSF and tissue samples
After five days of sleep deprivation, the fatigued rats
were anesthetized with 350 mg/kg ip chloral hydrate, and
CSF (60-100 ml) was drawn from the cisterna magna using a
glass capillary with a tip of approximately 300 mm in size.
The surgery was performed carefully to avoid blood
contamination. The CSF was then prepared for an IL-6
enzyme-linked immunosorbent assay (ELISA).
The brain samples were placed in sterile PBS containing a
protease inhibitor cocktail (0.2 mM 4-[2-aminoethyl]benze-
nesulfonyl fluoride, HCl [AEBSF], 1 mg/ml aprotinin, 1 mM
benzamidine, 1 mM EDTA, 10 mg/ml leupeptin and 10 mg/
ml of pepstatin) and then homogenized and centrifuged
(10000 g, 30 min, 4 C˚). Subsequently, the supernatant was
removed and stored at -70 C˚. All of the samples were
assayed for immunoreactive IL-6 using a validated rat-
specific ELISA kit (IL-6, Fuji Lebio, Tokyo, Japan). Briefly,
total brain samples were added to wells and incubated for
two hours. Then, the conjugate was added and incubated
for another two hours. After washing five times, the
substrate solution was added and incubated for 30 minutes.
Finally, the stop solution was added and measurements
were obtained at 450 nm.
& RESULTS
Effects of fatigue on the cerebral infarction area
To study the impact of fatigue on the severity of stroke,
we compared the cerebral infarction area between the
fatigued and control groups. Figure 1A presents represen-
tative results of the effects of MCA occlusion on infarction
size in both groups: the control group and the fatigued
CLINICS 2014;69(6):426-432 IL-6 contributes to stroke severity
Lei H et al.
427
group (rats deprived of sleep for five consecutive days).
Coronal sections were obtained by cutting brain slices at
distances of 2, 4, 6, 8 and 10 mm from the rostral extremity
of the frontal cortex. The white-colored areas represent the
infraction regions in these sections. Figure 1B shows the
percentage of infarction area in rats that underwent MCAO.
More severe cerebral infarction was observed in the fatigued
rats and the infarct ratio was 23.4%. The infarct ratio was
significantly increased in the fatigued rats compared with
that in the control group (8%, p,0.05).
Coagulation parameter changes in rat plasma
during fatigue
Figure 2A shows the plasma changes in PT, APTT and TT
in the fatigued and control groups. None of these
parameters showed significant changes in the fatigued rats
compared with those of the control group. Figure 2B shows
the plasma changes in fibrinogen in the fatigued and control
groups. The level of fibrinogen increased significantly in the
fatigued rats compared with that in the control group.
Involvement of IL-6 in fibrinogen synthesis during
fatigue
As shown in Figure 3A, the plasma fibrinogen level
showed slight changes in rats deprived of sleep for one day
(F1 group) compared with that in the control group
(401.7 mg/dl vs. 417.9 mg/dl). Furthermore, the level was
significantly increased in rats deprived of sleep for three
days (F3 group); in that group, the fibrinogen level was
532.5 mg/dl. The fibrinogen concentration reached a max-
imum value in rats deprived of sleep for five consecutive
days (F5 group), with a fibrinogen level of 793.1 mg/dl.
To study whether IL-6 was involved in fibrinogen
synthesis during fatigue, we also measured the levels of
IL-6 in rats deprived of sleep for various time intervals. As
shown in Figure 3B, the serum IL-6 level started to increase
in the F1 group, rose gradually in the F3 group and reached
a peak in the F5 group. The levels of serum IL-6 were
301.6 pg/ml, 438.4 pg/ml and 1004.6 pg/ml, respectively
(the level of IL-6 in the control mice was 212.6 pg/ml, as
shown in Figure 3A). As indicated by Figure 3C, the levels
Figure 1 - The cerebral infarction area after MCAO in rats from the various groups. Figure 1A shows representative photographs of
coronal sections of rat brains. From left to right are the MCAOs in the control rats and fatigued rats, respectively. The white areas
represent the infarct regions. Figure 1B shows the infarct ratios in rats from the various groups. The infarct ratio was calculated as the
percentage of infarcted tissue per ipsilateral hemisphere. In the control group, the infarct ratio was 8%. In the fatigued group, the
infarct ratio was markedly increased (24%) over that of the control group. *, p,0.05.
Figure 2 - Changes in plasma coagulation parameters in fatigued rats. The levels of fibrinogen increased significantly compared with
those in the control group. Other parameters, such as PT, APTT and TT, remained unchanged. Values are represented as means¡ S.E.M.
*, p,0.05.
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of IL-6 in serum were significantly increased in fatigued rats,
consistent with our previous results, and no detectable IL-6
was observed in the IL-6 knockout mice. To identify whether
IL-6 was involved in fibrinogen synthesis, IL-6 knockout mice
were included in the subsequent studies. Consistent with the
previous results, the level of fibrinogen increased significantly
in fatigued wild-type mice. The IL-6-/- mice showed signifi-
cantly increased fibrinogen levels compared to the wild-type
mice, but the fibrinogen levels in the fatigued IL-6-/- mice were
not as high as those in the fatigued wild-type mice, suggesting
that the elevation of fibrinogen levels during fatigue was at
least partially attenuated in the IL-6-/- mice (Figure 3D, wild-
type: 402 mg/dl and 797.9 mg/dl; IL-6 -/-: 383 mg/dl and
593 mg/dl). At the same time, treating IL-6-/- mice with
recombinant human IL-6 (Pharma Technology, Hannover,
Lower Saxony, Germany) greatly increased the levels of
fibrinogen compared with those in the untreated IL-6-/- mice
(fibrinogen: 593 mg/dl and 745.4 mg/dl, respectively).
Measurements of cerebral infarction area in
fatigued mice
The fatigued mice that underwent sleep deprivation were
divided into three groups: 1) fatigued wild-type mice; 2)
fatigued IL-6-knockout mice; and 3) fatigued wild-type mice
treated with bezafibrate. As shown in Figure 4, compared to
wild-type animals, the IL-6-/- mice displayed significantly
less brain injury after MCAO procedures, demonstrated by
the decreased infarction area. At the same time, treating
wild-type mice with bezafibrate, which decreased the
fibrinogen levels, also provided protection from MCAO-
induced brain injury.
& DISCUSSION
Our results revealed that fatigued rats experienced
significantly more brain injury after MCAO compared to
their wild-type counterparts. In this study, we used the
animal model of fatigue established by Tanaka et al.
Although this model was created to study central fatigue,
the swimming time of the fatigued rats also decreased
sharply. When kept in water, the animals were unable to
assume a resting position or sleep soundly as they
attempted to avoid the water. Notably, sleep deprivation
caused a wide range of neuropsychological and homeostatic
changes that could not be ascribed to simple fatigue (19,20).
Most of these alterations due to sleep deprivation could
have interfered with the cerebral response to ischemic
stress. Therefore, we compared brain infarction area in rats
Figure 3 - Involvement of IL-6 in fibrinogen synthesis. Figures 3A and 3B show the changes in plasma fibrinogen and IL-6 levels in rats
deprived of sleep for various numbers of days (F1, F3 and F5: deprived of sleep for one day, three days and five days, respectively).
Figure 3C shows the levels of IL-6 in the plasma of wild-type mice and IL-6-/-mice. Figure 3D shows the levels of fibrinogen in the plasma
of wild-type mice, IL-6-/- mice and IL-6-/- mice treated with recombinant human IL-6. The white column represents the control group.
The black column represents the fatigued group.
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performing an acute exercise protocol. In this model of
fatigue, the rats were allowed to run until exhaustion, which
was defined as the point at which the rats failed to escape
the shock grid and had to be repositioned manually to the
front of the treadmill on three consecutive occasions (21).
This acute exhaustive exercise did not cause neuropsycho-
logical or homeostatic changes and could be considered to
represent simple fatigue. Subsequent results revealed that
the infarction area also increased significantly in rats after
performing exhaustive exercise (Supplemental Figure 1).
These results indicated that fatigue, whether physical or
mental, aggregated the brain injury induced by MCAO.
Moreover, we explored the underlying mechanisms.
Fibrinogen is acute-phase protein, and it serves as a
nonspecific marker of inflammatory disease (22). It also
has important hemostatic properties due to its effects on
platelet aggregation and endothelial function. Fibrinogen is
a major determinant of plasma viscosity. High levels of
fibrinogen in the plasma might reduce blood flow and
predispose to thrombosis. High levels of fibrinogen have
been associated with an increased risk of cardiovascular
disease and stroke (23,24). In our studies, we found that the
level of fibrinogen increased significantly in fatigued rats.
Whether increased levels of fibrinogen reflected active
involvement in the pathogenesis of stroke severity during
fatigue or were merely a nonspecific marker of inflamma-
tory disease was not clear. Bezafibrate, a classic lipid-
lowering drug, was used to lower plasma fibrinogen
concentrations as well (25). In this study, we treated
fatigued mice with bezafibrate to lower the fibrinogen
levels (data not shown) and then submitted these mice to
MCAO surgery. The bezafibrate-treated mice showed
significantly decreased brain infarction areas compared to
the control mice, indicating that fibrinogen was involved in
the pathogenesis of stroke severity.
IL-6 is a multifunctional cytokine. Numerous studies have
found IL-6-responsive elements in the fibrinogen gene
promoter (26). IL-6 and its receptor were involved in
fibrinogen synthesis (27). To determine whether elevated
fibrinogen levels during fatigue were mediated by IL-6, we
first measured the levels of IL-6 in fatigued rats and then
examined the fibrinogen concentrations in IL-6-/- mice and
wild-type controls. A significant increase in IL-6 levels was
observed in the serum of fatigued rats. Because the fatigue
model we examined in this study was a mental model, we
also measured the levels of IL-6 in the cerebral spinal fluid
(CSF) and brain tissue. Fatigue increased the expression of IL-
6 in the CSF and brain as well (Supplemental Figures 2A and
2B). Consistent with previous results, fatigue increased the
expression of fibrinogen in the wild-type controls. A marked
reduction in fibrinogen levels was seen in the fatigued IL-6-/-
mice compared to their wild-type counterparts, whereas no
Figure 4 - Measurements of the cerebral infarction areas.
Figure 4A shows representative photographs of coronal sections
of mouse brains after MCAO. From left to right are the brains of
fatigued mice in the control group, in the IL-6-/- group and in the
bezafibrate-treated group, respectively. Figure 4B shows the
infarct volumes in the three groups. *, p,0.05 (compared with
the fatigued group).
Supplemental Figure 1 - Cerebral infarction area after MCAO in rats of different groups. Supplemental figure 1A shows representative
photographs of coronal sections of rat brains. From left to right are the MCAO in the control rats and exhaustive rats respectively. The
white areas represent the infarct regions. Supplemental figure 1B shows the infarct ratio in rats of different groups. The infarct ratio
was calculated as the % infarcted tissue per ispilateral hemisphere. In the control group, the infarct ratio was 8%. In the fatigue group,
the infarct ratio was markedly increased when compared with control group (the ratio was 24%). *, p,0.05.
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difference was seen between fatigued wild-type mice and IL-
6-/- mice treated with recombinant human IL-6. The reduc-
tion in brain injury caused by MCAO during fatigue in IL-6-/-
mice suggested that the lack of IL-6 protected against MCAO-
induced brain injury. In conclusion, our results explained
why fatigued subjects were more prone to severe brain injury
induced by MCAO than were control subjects, and IL-6
might serve as a biological marker for fatigue in our fatigue
model. To the best of our knowledge, fatigue has typically
been considered to be a subjective symptom, and no specific
marker has been identified to measure it. People usually
underestimate the importance of unusual fatigue, although it
might be associated with sudden death due to coronary heart
disease or stroke. Our studies demonstrated that progres-
sively increasing levels of IL-6 during fatigue constitute a
dangerous signal because they lead to increased expression
of fibrinogen, which would eventually aggregate ischemic
brain injury. Monitoring the level of IL-6 or the level of
fibrinogen during fatigue could help us objectively assess the
level of fatigue a person is experiencing. Inhibiting excessive
fibrinogen production or reducing the levels of IL-6 might be
two effective ways of preventing severe brain injury during
fatigue. Because a slight but significant increase in fibrinogen
was still observed in fatigued IL-6-/- mice, other pathways
might also involve fibrinogen synthesis. There were some
limitations of this study that should be acknowledged. First,
IL-6 was not the only mediator that induced the expression of
fibrinogen during fatigue, and these other mediators should
be explored in future studies. Second, the fatigue model
(sleep deprivation) applied here was a mental model,
whereas combined fatigue (both mental and physical) is
more prevalent among people in everyday life; we should
therefore develop a more representative fatigue model to
study the relationship between the severity of combined
fatigue and the volume of the infarcted cerebral area.
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